Company Profile

ImmunoGen, Inc. is a commercial-stage biotechnology company. The Company is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its ELAHERE (Mirvetuximab Soravtansine) is a first-in-class ADC targeting folate receptor alpha (FRa), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Its Pivekimab sunirine (PVEK), is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. The Company is advancing PVEK in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).

Employees

277

Sector

Biotechnology & Medical Research

More about the company

20/02/24	AbbVie CEO to Retire; COO Robert Michael Named Successor	MT
13/02/24	BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	AN
13/02/24	Biopharma Credit Secures $51 Million Loan Repayment from US Biotech ImmunoGen	MT
12/02/24	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Global BMI Index	CI
12/02/24	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P TMI Index	CI
12/02/24	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Biotechnology Select Industry Index	CI
12/02/24	Top Stories at Midday: Bezos Sells Nearly 12 Million Amazon Shares; Diamondback's $26 Billion Endeavor Energy Deal; Citigroup's Risk Management Procedures Rebuked; AbbVie Buys ImmunoGen	MT
12/02/24	AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance	MT
12/02/24	AbbVie: acquisition of ImmunoGen finalized
12/02/24	AbbVie Acquires ImmunoGen for $31.26 per Share	MT
12/02/24	Immunogen, Inc. Announces Board Changes	CI
11/02/24	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index	CI
11/02/24	AbbVie Inc. completed the acquisition of ImmunoGen, Inc. from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc., State Street Corporation, The Vanguard Group, Inc. and others.	CI

04/12/23	Piper Sandler Downgrades ImmunoGen to Neutral From Overweight, Raises Price Target to $31 From $24	MT
01/12/23	Barclays Downgrades ImmunoGen to Equalweight From Overweight, Raises Price Target to $31 From $27	MT
01/12/23	Deutsche Bank Downgrades ImmunoGen to Hold From Buy, Adjusts Price Target to $31 From $25	MT
01/12/23	BMO Capital Downgrades ImmunoGen to Market Perform From Outperform, Price Target is $31	MT
01/12/23	Guggenheim Downgrades ImmunoGen to Neutral From Buy, Adjusts Price Target to $31 From $25	MT

12/02/24	AbbVie Completes Acquisition of ImmunoGen	PR
01/02/24	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
04/01/24	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
03/01/24	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
10/12/23	ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH	BU

12/02/24	Diamondback Energy : Abbvie, Diamondback Energy, Gilead...les valeurs à suivre aujourd'hui à Wall Street
12/02/24	Abbvie : abaisse ses perspectives après le rachat d'Immunogen
12/02/24	AbbVie : acquisition d'ImmunoGen finalisée
02/02/24	Omzetdaling Abbvie valt mee
22/01/24	HBM bleibt nach neun Monaten in den roten Zahlen

Manager	Title	Age	Since
Stacy Coen PRN	Corporate Officer/Principal	55	02/06/2020
Theresa Wingrove CTO	Chief Tech/Sci/R&D Officer	68	23/01/2011

ImmunoGen, Inc. Share Price

Stocks

IMGN

US45253H1014

Biotechnology & Medical Research

Latest news : ImmunoGen, Inc.

Analysts' recommendations : ImmunoGen, Inc.

Press Releases : ImmunoGen, Inc.

News in other languages : ImmunoGen, Inc.

Managers and Directors : ImmunoGen, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/02/24	Richard Wallace	Issuer sale	Director	354,013	0.1267%
12/02/24	Daniel Char	Issuer sale	General Counsel	423,825	0.1517%
12/02/24	Mark Enyedy	Issuer sale	CHIEF EXECUTIVE OFFICER; Director	5,071,495	1.8154%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMMUNOGEN, INC.	-.--%	+6.73%	-	-	8.36B
LONZA GROUP AG	-0.71%	-6.35%	-2.99%	+9.59%	45.48B
REVOLUTION MEDICINES, INC.	+0.21%	-2.98%	+337.74%	+519.55%	43.68B
IQVIA HOLDINGS INC.	+1.74%	-2.24%	+39.82%	+20.76%	43.09B
BEONE MEDICINES AG	+1.38%	-3.28%	+6.84%	+67.62%	39.4B
CELLTRION, INC.	-1.44%	-5.26%	+8.97%	+39.76%	31.91B
ASCENDIS PHARMA A/S	+0.87%	-2.60%	-	-	17.31B
MEDPACE HOLDINGS, INC.	+0.75%	-0.64%	+19.75%	+110.17%	16.4B
EUROFINS SCIENTIFIC SE	-0.31%	-2.78%	+10.78%	+31.02%	14.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.93%	-3.55%	+82.00%	+41.17%	13.28B
Average	+0.44%	-3.57%	+62.86%	+104.96%	29.42B
Weighted average by Cap.	+0.40%	-3.67%	+74.57%	+124.26%